Drug Profile
Pegylated erythropoietin - PharmaEssentia
Alternative Names: PEG-EPO - PharmaEssentiaLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator PharmaEssentia Corporation
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Anaemia in Taiwan (Parenteral)
- 19 Sep 2019 Pegylated erythropoietin is still in preclinical development in Anaemia in Taiwan (Parenteral) (PharmaEssentia pipeline September 2019)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Anaemia in Taiwan (Parenteral)